Journal
PEDIATRIC BLOOD & CANCER
Volume 61, Issue 12, Pages 2307-2309Publisher
WILEY-BLACKWELL
DOI: 10.1002/pbc.25102
Keywords
alemtuzumab; autoimmunity; sickle cell disease; stem cell transplant; thyroid dysfunction
Categories
Funding
- NIDDK NIH HHS [T32 DK065522] Funding Source: Medline
Ask authors/readers for more resources
Allogenic hematopoietic cell transplantation (alloHCT) is currently the only curative treatment option for patients with sickle cell disease. Alemtuzumab is a monoclonal antibody directed against CD52 positive cells used in myeloablative conditioning regimens for alloHCT. Its use has been associated with development of autoimmune disease in adult patients with rheumatologic conditions. We report on three cases of new onset autoimmune thyroid disease after alloHCT treatment with alemtuzumab in pediatric patients with sickle cell disease. Pediatr Blood Cancer 2014;61:2307-2309. (c) 2014 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available